Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124565 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01124565 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT01124565, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.
Interventions
- DRUG RT001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01124565
The ClinicalTrials.gov registry entry for NCT01124565 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RT001 is the first listed.
NCT01124565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01124565 about?
NCT01124565 is a clinical study titled "Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults". This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.
What is the current status of trial NCT01124565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2010-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01124565?
The interventions under investigation include: RT001 (DRUG).
Who is sponsoring clinical trial NCT01124565?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.